Schairer, Catherine http://orcid.org/0000-0001-7671-4972
Hablas, Ahmed
Eldein, Ibrahim AbdelBar Seif
Gaafar, Rabab
Rais, Henda
Mezlini, Amel
Ayed, Farhat Ben
Ayoub, Wided Ben
Benider, Abdellatif
Tahri, Ali
Khouchani, Mouna
Aboulazm, Dalia
Karkouri, Mehdi
Eissa, Saad
Pfeiffer, Ruth M.
Gadalla, Shahinaz M.
Swain, Sandra M.
Merajver, Sofia D.
Brown, Linda Morris
Soliman, Amr S.
Funding for this research was provided by:
National Cancer Institute (R25 CA112382)
Article History
Received: 2 April 2019
Accepted: 10 April 2019
First Online: 22 April 2019
Compliance with ethical standards
:
: Sandra Swain reports receiving honoraria from Novartis, personal fees from Cardinal Health, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, Genomic Health, Inivata, Peiris Pharmaceuticals, Tocagen; research support from Genentech; travel and accommodations from Caris Centers of Excellence, Daiichi-Sankyo, Eli Lilly & Co., Genentech/Roche, NanoString Technologies; and remuneration from AstraZeneca for participation on OlympiA IDMC. The other authors declare they have no conflicts of interest.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committees.
: Informed consent was obtained from all study participants.